Evotec SE (EVO)
| Market Cap | 1.25B |
| Revenue (ttm) | 844.79M |
| Net Income (ttm) | -182.89M |
| Shares Out | 177.30M |
| EPS (ttm) | -1.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,467 |
| Open | 3.500 |
| Previous Close | 3.640 |
| Day's Range | 3.380 - 3.500 |
| 52-Week Range | 2.850 - 12.000 |
| Beta | 1.05 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+136.69%) |
| Earnings Date | Nov 6, 2024 |
About EVO
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exsci... [Read more]
Financial Performance
In 2023, Evotec SE's revenue was 781.43 million, an increase of 3.99% compared to the previous year's 751.45 million. Losses were -83.91 million, -52.23% less than in 2022.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to one analyst, the rating for EVO stock is "Strong Buy" and the 12-month stock price forecast is $8.0.
News
Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just - Evotec Biologics' J.POD® technology offers a paradigm shift in biomanufactur...
Scientist.com and Evotec Partner to Accelerate Drug Discovery and Development
SAN DIEGO--(BUSINESS WIRE)-- #Evotec--Life science leader Evotec partners with Scientist.com to streamline access to its cutting-edge drug discovery and development solutions.
Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery
WALTHAM, Mass.--(BUSINESS WIRE)--Evotec SE and X-Chem announces a collaboration agreement focused on accelerating early-stage drug discovery. .
Evotec Announces Change in Management Board
Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024 Distribution of responsibilities across other Management Board functions HAMBURG, GERMANY / ACCESSWIRE / September 3, 2...
Evotec: Weak Performance, But Long-Term Potential Is There
Evotec's 28% decline is due to negative EBITDA despite solid top-line revenue growth, highlighting the need for patience in speculative investments. The company is restructuring, focusing on biologics...
Evotec SE (EVO) Q2 2024 Earnings Call Transcript
Evotec SE (NASDAQ:EVO) Q2 2024 Earnings Conference Call August 14, 2024 8:00 AM ET Company Participants Volker Braun - Executive Vice President, Head of Global Investor Relations and ESG Christian Wo...
Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths
Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve reve...
Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
Key scientific achievements drive the expansion of the pipeline of molecular glue degraders Performance-based and programme-based payments of in total US$ 75 m to Evotec HAMBURG, GERMANY / ACCESSWIRE ...
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research HAMBURG, GERMANY / ACCESSWIRE / August 8, 2024 / Evotec SE (F...
Evotec SE Reports First Half-year 2024 Results on 14 August 2024
HAMBURG, GERMANY / ACCESSWIRE / August 7, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first half-year of 2...
Evotec Provides Guidance Update
Navigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just - Evotec Biologics with mid double-digit revenue growth versus strong comparable basis Adjusted EBITDA impac...
Evotec SE Provides Guidance Update
HAMBURG, GERMANY / ACCESSWIRE / August 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its...
Evotec and Pfizer Collaborate to Advance Drug Discovery in France
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG, GERMANY / ACCESSWIRE / July 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)...
Just - Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz
Just - Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Furthe...
Just - Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
Just - Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD's Manufacturing Optimization Program Manufacturing solution includes sea...
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research HAMBUR...
Evotec SE: Results of the Annual General Meeting 2024
Most agenda items adopted with great majority Annual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario Polywka HAMBURG...
Evotec SE (EVO) Q1 2024 Earnings Call Transcript
Evotec SE (NASDAQ:EVO) Q1 2024 Earnings Conference Call May 22, 2024 8:00 AM ET Company Participants Volker Braun - EVP Head of Global IR and ESG Mario Polywka - Interim CEO Laetitia Rouxel - CFO Mat...
Evotec SE to Announce Results for First Quarter 2024 on 22 May 2024
HAMBURG, GERMANY / ACCESSWIRE / May 15, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first quarter of 2024...
Bayer and Evotec Collaborate to Advance Precision Cardiology
BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS J...
Evotec SE (EVO) Q4 2023 Earnings Call Transcript
Evotec SE (EVO) Q4 2023 Earnings Call Transcript
Evotec: Still A Speculative Buy After A Significant Decline
Evotec SE's stock has declined over 30% in a single day, marking a 5-year decline of over 56%. The company's 2023A results met guidance, but the market expected more from the 2024E forecasts.
Evotec shares lose a third of their value on cloudy outlook
Shares of German biotech Evotec lost a third of their value on Wednesday on an uncertain outlook as it named a new chief executive.
Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth
FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M EVOTEC'S REP...
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) has appointed Dr Christian Wojczewski a...